Detection and Characterization of Infections and Infection Susceptibility
This study will examine the causes of immune disorders affecting white blood cells, which defend against infections and will try to develop better means of diagnosis and treatment of these immune disorders.
Patients known to have or suspected of having increased susceptibility to infections and their blood relatives may be eligible for this study, at the discretion of the principal investigator. Patients and family members may undergo the following procedures:
- Personal and family medical history.
- Physical examination and blood and urine tests.
- Studies of breathing function (pulmonary function testing)
- Dental examination.
- Eye examination.
- Microscopic examination of saliva, wound drainage or tissues removed for medical reasons for cell, hormone or DNA studies.
In addition, patients may be asked permission for investigators to obtain their medical records, previous test results, or radiographic studies and to undergo imaging studies, such as a chest X-ray, CT scan or MRI scan.
Chronic Granulomatous Disease
Genetic Immunological Deficiencies
Hyperimmunoglobulin-E Recurrent Infection Syndrome
|Study Design:||Time Perspective: Retrospective|
|Official Title:||Screening Protocol for Detection and Characterization of Infections and Infection Susceptibility|
- The primary endpoint of this study will be determination of a discretediagnosis of an infecting agent, an underlying susceptibility trait, or both. [ Time Frame: Within 2 visits ] [ Designated as safety issue: No ]
|Study Start Date:||November 2006|
This screening study is designed to evaluate patients with suspected or identified recurrent or unusual infections and their family members for clinical and in vitro correlates of exposure and susceptibility. It will allow for up to 2 visits to obtain blood, urine, saliva, stool, skin biopsy, or wound drainage from such patients or their family members for research studies related to understanding the nature of the infection as well as the genetic and biochemical bases of these diseases. Patients determined by initial evaluation to be of interest for additional study or treatment will be asked to provide consent for enrollment into an appropriate NIH follow-up study. The present study will enroll up to 1500 patients and family members over the next 15 years.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00404560
|Contact: Cathleen Frein, R.N.||(301) email@example.com|
|Contact: Steven M Holland, M.D.||(301) firstname.lastname@example.org|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL) 800-411-1222 ext TTY8664111010 email@example.com|
|Principal Investigator:||Steven M Holland, M.D.||National Institute of Allergy and Infectious Diseases (NIAID)|